Get the Stockscreener App
8.60
9.57%
-0.91
Pre-market:
8.83
0.23
+2.67%
Cartesian Therapeutics Inc stock is traded at $8.60, with a volume of 259.82K.
It is down -9.57% in the last 24 hours and up +16.53% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
See More
Previous Close:
$9.51
Open:
$9.69
24h Volume:
259.82K
Relative Volume:
1.07
Market Cap:
$252.68M
Revenue:
$1.78M
Net Income/Loss:
$-151.77M
P/E Ratio:
-1.4832
EPS:
-5.7981
Net Cash Flow:
$-79.40M
1W Performance:
+46.76%
1M Performance:
+16.53%
6M Performance:
-4.12%
1Y Performance:
-17.47%
1-Day Range:
$8.58
$9.69
1-Week Range:
$6.59
$9.75
52-Week Range:
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
8.60 | 252.68M | 1.78M | -151.77M | -79.40M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
New partnership gives Cartesian Therapeutics another shot at autoimmune disease market - MSN
RNAC Q1 2026 Earnings: Disappointing EPS Miss Yet Stock Surges 18%Earnings Weakness Phase - newsline.com
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
Cartesian climbs on licensing deal with WestGene for CAR-T therapies - MSN
RNAC: Directors elected and all proposals passed with strong support; no stockholder questions submitted - TradingView
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Cartesian Eyes Multiple 2026-2027 Readouts As Descartes-08 Advances Toward Potential BLA - RTTNews
RNAC Reiterated by Wedbush -- Price Target Maintained at $38.00 - GuruFocus
RNAC Reiterated by BTIG -- Price Target Maintained at $44.00 - GuruFocus
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40 - Moomoo
Morgan Stanley Smith Barney (RNAC) lists exercises, vesting and a 3,924-share resale - Stock Titan
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre - GuruFocus
WestGene Biopharma to collaborate with Cartesian Therapeutics on in vivo CAR-T for autoimmune disease - Traders Union
Why Is Cartesian Therapeutics Stock Trading Higher Today?Cartesian Therapeutics (NASDAQ:RNAC) - Benzinga
Cartesian partners with WestGene for in vivo autoimmune CAR-T - grafa.com
Cartesian inks licensing deal with WestGene (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics stock jumps on WestGene partnership deal - Investing.com UK
Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com - Investing.com Australia
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance - TipRanks
Cartesian strikes licensing agreement with WestGene - The Pharma Letter
Cartesian Therapeutics (RNAC) licenses in vivo CAR-T delivery tech from WestGene - Stock Titan
Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases - TradingView
Experimental in vivo CAR-T for myasthenia gravis could skip lab manufacturing - Stock Titan
Cartesian Therapeutics (RNAC) Slides 10.8% as Stock Tests Key Support LevelsVol Target Rebalance - newsline.com
Cartesian Therapeutics (RNAC) Faces Sharp Decline, Testing Key Support LevelsADD Alert - newsline.com
[144] Cartesian Therapeutics, Inc. SEC Filing - Stock Titan
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics (RNAC) Rises 3.33% as Stock Holds Above Key SupportHedge Fund Exposure - The Legal Advocate
Cartesian Therapeutics (RNAC) Gains 4.6% as Biotech Sector Shows Renewed InterestInstitutional Sentiment - The Legal Advocate
H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC) - The Globe and Mail
Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter
Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus
RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus
Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com
Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang
Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart
Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures - marketscreener.com
Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz
Cartesian Therapeutics IncEnters loan and security agreement on May 22SEC filing - marketscreener.com
Cartesian Secures Major Loan Facility to Extend Runway - TipRanks
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - The Manila Times
Milos Miljkovic to Depart Cartesian Therapeutic as Chief Medical Officer; Separation Agreement Expected - TradingView
Cartesian Therapeutics secures up to 150 million dollar credit facility to extend cash runway to 2028 - Traders Union
Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway - Stock Titan
Cartesian Therapeutics Secures up to $150 Million of - GlobeNewswire
Cartesian Therapeutics Inc. (RNAC) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Stock Ticks HigherDividend Cut Risk - The Legal Advocate
Cartesian Therapeutics (RNAC) Q1 2026 Earnings Miss: Breaking Down the NumbersEarnings Revision Upgrade - Newser
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):